Switch theme
Sign up to access all valuation multiples
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
2012
683
LTM Revenue $457M
LTM EBITDA -$219M
$4.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Axsome Therapeutics has a last 12-month revenue of $457M and a last 12-month EBITDA of -$219M.
In the most recent fiscal year, Axsome Therapeutics achieved revenue of $386M and an EBITDA of -$273M.
Axsome Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Axsome Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $271M | $386M | XXX | XXX | XXX |
| Gross Profit | $44.8M | $245M | XXX | XXX | XXX |
| Gross Margin | 17% | 63% | XXX | XXX | XXX |
| EBITDA | -$225M | -$273M | XXX | XXX | XXX |
| EBITDA Margin | -83% | -71% | XXX | XXX | XXX |
| Net Profit | -$187M | -$239M | XXX | XXX | XXX |
| Net Margin | -69% | -62% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 23, 2025, Axsome Therapeutics's stock price is $104.
Axsome Therapeutics has current market cap of $5.1B, and EV of $4.9B.
See Axsome Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9B | $5.1B | XXX | XXX | XXX | XXX | $-5.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 23, 2025, Axsome Therapeutics has market cap of $5.1B and EV of $4.9B.
Axsome Therapeutics's trades at 10.8x LTM EV/Revenue multiple, and -22.6x LTM EBITDA.
Analysts estimate Axsome Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Axsome Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.9B | XXX | XXX | XXX |
| EV/Revenue | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | -18.1x | XXX | XXX | XXX |
| P/E | -17.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -38.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAxsome Therapeutics's NTM/LTM revenue growth is 61%
Axsome Therapeutics's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Axsome Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Axsome Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Axsome Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -71% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -9% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 49% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 157% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Axsome Therapeutics acquired XXX companies to date.
Last acquisition by Axsome Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Axsome Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Axsome Therapeutics founded? | Axsome Therapeutics was founded in 2012. |
| Where is Axsome Therapeutics headquartered? | Axsome Therapeutics is headquartered in United States of America. |
| How many employees does Axsome Therapeutics have? | As of today, Axsome Therapeutics has 683 employees. |
| Who is the CEO of Axsome Therapeutics? | Axsome Therapeutics's CEO is Dr. Herriot Tabuteau, M.D.. |
| Is Axsome Therapeutics publicy listed? | Yes, Axsome Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Axsome Therapeutics? | Axsome Therapeutics trades under AXSM ticker. |
| When did Axsome Therapeutics go public? | Axsome Therapeutics went public in 2015. |
| Who are competitors of Axsome Therapeutics? | Similar companies to Axsome Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Axsome Therapeutics? | Axsome Therapeutics's current market cap is $5.1B |
| What is the current revenue of Axsome Therapeutics? | Axsome Therapeutics's last 12-month revenue is $457M. |
| What is the current EBITDA of Axsome Therapeutics? | Axsome Therapeutics's last 12-month EBITDA is -$219M. |
| What is the current EV/Revenue multiple of Axsome Therapeutics? | Current revenue multiple of Axsome Therapeutics is 10.8x. |
| What is the current EV/EBITDA multiple of Axsome Therapeutics? | Current EBITDA multiple of Axsome Therapeutics is -22.6x. |
| What is the current revenue growth of Axsome Therapeutics? | Axsome Therapeutics revenue growth between 2023 and 2024 was 43%. |
| Is Axsome Therapeutics profitable? | Yes, Axsome Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
